» Articles » PMID: 15480339

Children and Adults with Primary Antibody Deficiencies Gain Quality of Life by Subcutaneous IgG Self-infusions at Home

Abstract

Background: A large number of children and adults with primary antibody deficiencies need lifelong IgG replacement therapy. It is mostly unknown what effect the choice of replacement therapy has on the patients' health-related quality of life (HRQOL) and treatment satisfaction (TS).

Objective: To investigate whether a switch from hospital-based intravenous IgG (IVIG) to home-based subcutaneous IgG (SCIG) therapy would improve the HRQOL and TS.

Methods: Fifteen children (<14 years; hospital-based IVIG therapy at enrollment) and 32 adults (> or =14 years; 22 on hospital-based IVIG and 10 on home-based SCIG therapy at enrollment) were included. Questionnaires were completed at baseline and at 6 and 10 months: the Child Health Questionnaire-Parental Form 50 (children) or Short Form 36 (adults), the Life Quality Index, and questions regarding therapy preferences.

Results: The SCIG home therapy was reported to give better health (P=.001) and improved school/social functioning (P=.02) for the children, reduced emotional distress (P=.02) and limitations on personal time for the parents (P=.004), and fewer limitations on family activities (P=.002). Adults switching therapy reported improved vitality (P=.04), mental health ( P=.05), and social functioning ( P=.01). Adults already on SCIG home therapy at enrollment retained high HRQOL and TS scores. The SCIG home therapy improved TS because it led to greater independence and better therapy convenience ( P <.05). The patients preferred the SCIG administration route and having the treatment at home.

Conclusions: Home-based SCIG therapy improves several important aspects of HRQOL and provides the patients with primary antibody deficiencies and their families with greater independence and better control of the therapy situation and daily life. SCIG home therapy is an appreciated therapeutic alternative for adults and children in need of lifelong IgG replacement therapy.

Citing Articles

Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction.

Mallick R, Hahn N, Scalchunes C Allergy Asthma Clin Immunol. 2025; 21(1):2.

PMID: 39773529 PMC: 11706029. DOI: 10.1186/s13223-024-00939-y.


Customizing subcutaneous immunoglobulin administration in primary antibody deficiency: patient-centric care perspectives.

Kobayashi R, Maltese J, Litzman J, Kreuwel H, Zekoll T, Kobayashi A Immunotherapy. 2024; 16(20-22):1235-1245.

PMID: 39648657 PMC: 11760218. DOI: 10.1080/1750743X.2024.2436343.


Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis.

Bril V, Lampe J, Cooper N, Kiessling P, Gardulf A J Comp Eff Res. 2024; 13(9):e230171.

PMID: 39115099 PMC: 11363182. DOI: 10.57264/cer-2023-0171.


Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.

Rao V, Kulm E, Grossman J, Buchbinder D, Chong H, Bradt J Blood Adv. 2024; 8(12):3092-3108.

PMID: 38593221 PMC: 11222951. DOI: 10.1182/bloodadvances.2023011000.


Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies - impact of drug packaging and administration method on patient reported outcomes.

Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O BMC Immunol. 2024; 25(1):18.

PMID: 38378441 PMC: 10880328. DOI: 10.1186/s12865-024-00608-0.